What is the preferred treatment between rituximab and methotrexate (MTX) for skin binding down in systemic sclerosis?

Rituximab vs Methotrexate for Skin Fibrosis in Systemic Sclerosis

Rituximab is superior to methotrexate for treating skin binding down in systemic sclerosis, demonstrating a statistically significant 8.44-point greater improvement in modified Rodnan skin score compared to placebo in the highest quality randomized controlled trial. 1

Evidence Hierarchy and Strength

The 2025 EULAR guidelines provide the most definitive evidence comparing these agents:

• Rituximab achieved an absolute mRSS improvement of -6.30 versus placebo's 2.14 (difference -8.44,95% CI -11.00 to -5.88; p<0.0001) at 24 weeks in a double-blind RCT of 56 patients 1
• Methotrexate showed only a trend toward improvement with approximately 5-point mRSS difference versus placebo (p=0.17) in the largest trial of 71 patients, which was not statistically significant 1

The rituximab trial represents Level 1b evidence with statistical significance, while methotrexate trials failed to achieve statistical significance despite trends favoring treatment 1, 2.

Clinical Practice Algorithm

First-Line Treatment Selection

For most patients with skin fibrosis:

• Start with mycophenolate mofetil (MMF) as first-line, which is the most commonly prescribed agent for diffuse cutaneous SSc with mean mRSS improvement of -4.90 points 3
• MMF addresses both skin thickening and potential interstitial lung disease simultaneously 3

Alternative first-line:

• Methotrexate 25 mg/week if MMF is not tolerated or if musculoskeletal involvement is predominant 1, 3
• Note that clinical trials only studied 10-15 mg/week doses; higher doses commonly used in practice (25 mg/week) lack formal SSc trial data 1, 4

Second-Line/Escalation Strategy

When first-line therapy fails or disease worsens:

• Rituximab should be strongly considered as the next step, given its superior efficacy data 1
• Dosing: 375 mg/m² intravenously once weekly for 4 consecutive weeks 1
• The open-label extension showed sustained improvement at 48 weeks with two courses (-8.88 mRSS change from baseline) 5

Other second-line options:

• Tocilizumab for early, inflammatory dcSSc (though phase 3 trial missed primary endpoint with p=0.10) 1
• Cyclophosphamide (oral or IV) 1
• Autologous hematopoietic stem cell transplantation for severe, progressive disease 1

Direct Comparison Context

A multicenter observational study of 326 early dcSSc patients showed no significant difference in mRSS improvement across methotrexate (n=65), MMF (n=118), cyclophosphamide (n=87), or no immunosuppressants at 12 months, with modest improvement in all groups 1. This real-world data suggests methotrexate's effectiveness may be limited compared to controlled trial expectations.

Safety Considerations

Methotrexate safety concerns: 1, 4

• Liver toxicity requiring regular monitoring
• Pancytopenia (complete blood counts needed)
• Potential teratogenicity
• Possible induction of lung injury/interstitial lung disease (critical concern in SSc patients)
• Few premature discontinuations in trials (number needed to harm: 16-34.5) 1

Rituximab safety profile: 1

• No difference in adverse events versus placebo in the primary trial
• Serious adverse events in extension phase: one cholangitis, one pneumococcal pneumonia 5
• Rare risks include pneumonitis, worsening ILD, infections, hypogammaglobulinemia 6

Critical Caveats

Methotrexate limitations:

• Both RCTs used relatively low doses (10-15 mg/week) 1
• The larger trial (n=71) failed to achieve statistical significance despite trends favoring treatment 2
• Bayesian re-analysis suggested 94-96% probability of improvement, but this doesn't overcome the primary analysis failure 1
• One-year treatment may be needed for statistically significant skin score improvement 7

Rituximab considerations:

• The Japanese trial used 375 mg/m² dosing, which differs from standard rheumatic disease dosing 1
• Most prescribers lack access to rituximab in some jurisdictions 1
• Cost and insurance approval may limit availability 1

Treatment Duration and Monitoring

For methotrexate:

• Minimum 6 months provides only subjective improvement 7
• One year of treatment needed for statistically significant objective skin score improvement 7
• Regular liver function tests and complete blood counts required 4

For rituximab:

• Initial response by 24 weeks 1
• Sustained improvement through 48 weeks with two courses 5
• Modified Rodnan skin score should be assessed at each visit (minimal clinically important difference: 3.5-5.3 points) 3

Bottom Line for Clinical Decision-Making

Rituximab demonstrates superior efficacy with statistically significant results, while methotrexate shows only non-significant trends. However, current treatment paradigms recommend MMF as first-line due to dual benefits for skin and lung, with rituximab reserved for inadequate responders or progressive disease 1, 3. Methotrexate serves as an alternative first-line option when MMF is contraindicated or for patients with prominent musculoskeletal features, but should not be chosen over rituximab when escalation is needed 1, 3.